FINWIRES · TerminalLIVE
FINWIRES

$INSM

22 stories mentioning INSMUpdated 35d ago

Every FINWIRES story that references INSM, newest first.

What are analysts saying about INSM?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on INSM?

Insider Trading

Insmed Insider Sold Shares Worth $1,469,442, According to a Recent SEC Filing

William Lewis, Director, Chair and CEO, on May 04, 2026, sold 10,699 shares in Insmed (INSM) for $1,469,442. Following the Form 4 filing with the SEC, Lewis has control over a total of 535,109 common shares of the company, with 301,185 shares held directly and 233,924 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1104506/000140205126000026/xslF345X05/wk-form4_1778098286.xml

$INSM
Wire

Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says

Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.Price: $152.47, Change: $+1.33, Percent Change: +0.88%

$INSM

Showing 21-22 of 22

Track with the FINWIRES app suite

FolioX
FolioX
Track INSM in your portfolio
WheelAI
WheelAI
Analyze INSM options with the wheel strategy
StockInsider
StockInsider
See market sentiment on INSM